Professor Dyfrig Hughes

Athro mewn Ffarmacoeconomeg / Cyfarwyddwr Ymchwil

  1. 2006
  2. Published

    Improving Outcomes for People with Skin Tumours including Melanoma: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Hughes, D. A. & Edwards, R. T., 21 Feb 2006, Unknown.

    Research output: Book/ReportCommissioned report

  3. Published

    Eliciting patients' preferences using a discrete choice experiment questionnaire: the role played by qualitative data in questionnaire design

    Hughes, D., Longo, M., Hughes, D. A., Myles, S. & Lisles, C., 1 Mar 2006.

    Research output: Contribution to conferencePaper

  4. Published

    Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone.

    Simpson, J. A., Hughes, D., Manyando, C., Bojang, K., Aarons, L., Winstanley, P., Edwards, G., Watkins, W. A. & Ward, S., 1 Mar 2006, In: British Journal of Clinical Pharmacology. 61, 3, p. 289-300

    Research output: Contribution to journalArticlepeer-review

  5. Published

    Health and economic outcomes: Why compliance matters

    Hughes, D. & Hughes, D. A., 1 Apr 2006.

    Research output: Contribution to conferencePaper

  6. Published

    Physchiatrist prescribing preferences and attitudes toward promotion

    Hughes, D., Menkes, D., Davies, R. & Hughes, D. A., 1 Apr 2006.

    Research output: Contribution to conferencePaper

  7. Published

    Rationing of drugs for rare diseases

    Hughes, D. & Hughes, D. A., 1 Apr 2006.

    Research output: Contribution to conferencePaper

  8. Published

    Back to basics: what is the relationship between dose and duration of drug action?

    Hughes, D. & Hughes, D. A., 1 May 2006.

    Research output: Contribution to conferencePaper

  9. Published
  10. Published

    Orphan drugs revisited: author's response.

    Hughes, D. & Hughes, D. A., 1 May 2006, In: Quarterly Journal of Medicine. 99, 5, p. 350-351

    Research output: Contribution to journalArticlepeer-review

  11. Published
  12. Published

    Prescription fee exemption research study

    Hughes, D., Myles, S., Hughes, D. A., Routledge, P. & Wales, D. F., 1 Jun 2006.

    Research output: Contribution to conferencePaper

  13. Published

    Clinical and econnomic importance of completion of therapy in the treatment of LRTIs

    Hughes, D. & Hughes, D. A., 1 Sept 2006.

    Research output: Contribution to conferencePaper

  14. Published

    Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?

    Hughes, D. & Hughes, D. A., 1 Nov 2006.

    Research output: Contribution to conferencePaper

  15. 2007
  16. Published

    AWMSG criteria for appraising new medicines.

    Hughes, D. & Hughes, D. A., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  17. Published

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Jan 2007, In: Value in Health. 10, 3, p. A109

    Research output: Contribution to journalArticlepeer-review

  18. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  19. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  20. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Co-careldopa intestinal gel (Duodopa).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  21. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Darunavir (Prezista)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  22. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  23. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Lymphoid blast CML and PH+ ALL.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  24. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Dexrazoxane (Savene)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  25. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Emtricitabine (Emtriva)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  26. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Idursulfase (Elaprase)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  27. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Parathyroid hormone (Preotact)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

Previous 1 2 3 4 5 6 7 8 ...18 Next